Harvard University

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Harvard University</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Harvard Yard</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Cambridge, Massachusetts, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.harvard.edu" target="_blank">harvard.edu</a></td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1636</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>Harvard Medical School, Harvard T.H. Chan School of Public Health, Harvard Stem Cell Institute</td>
</tr>
<tr>
<td class="label">Total Enrollment</td>
<td>~24,000 students</td>
</tr>
<tr>
<td class="label">Nobel Laureates</td>
<td>161 (affiliated)</td>
</tr>
</table>

Harvard University

Introduction

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Harvard University</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Harvard Yard</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Cambridge, Massachusetts, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.harvard.edu" target="_blank">harvard.edu</a></td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1636</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>Harvard Medical School, Harvard T.H. Chan School of Public Health, Harvard Stem Cell Institute</td>
</tr>
<tr>
<td class="label">Total Enrollment</td>
<td>~24,000 students</td>
</tr>
<tr>
<td class="label">Nobel Laureates</td>
<td>161 (affiliated)</td>
</tr>
</table>

Harvard University

Introduction

Harvard University, founded in 1636, is the oldest institution of higher education in the United States and one of the world's most prestigious research universities. Located in Cambridge, Massachusetts, Harvard has been at the forefront of neurodegenerative disease research for decades, with groundbreaking discoveries in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and other neurological conditions [hu1].

The university's contribution to neurodegeneration research spans basic science discoveries, translational research, clinical trials, and training the next generation of neuroscientists. Harvard researchers have made fundamental contributions to understanding amyloid biology, tau pathology, neuroinflammation, and genetic risk factors for neurodegenerative diseases [hu2].

Organizational Structure

Harvard Medical School

Harvard Medical School (HMS) is the primary engine of Harvard's neurodegeneration research enterprise. With over 600 faculty members in the Department of Neurology alone, HMS conducts world-leading research across all major neurodegenerative diseases [hu1].

Key Research Areas

• Alzheimer's Disease and Related Dementias: Amyloid and tau biology, biomarkers, clinical trials
• Movement Disorders: Parkinson's disease, Huntington's disease, ataxias
• Motor Neuron Disease: ALS and frontotemporal dementia
• Neuroimmunology: Multiple sclerosis, autoimmune encephalitis
• Neurogenetics: Genetic risk factors, gene therapy approaches

Harvard T.H. Chan School of Public Health

The School of Public Health contributes to neurodegeneration research through:

• Neuroepidemiology: Population-based studies of dementia risk factors
• Environmental Neurology: Air pollution, vascular risk factors
• Biostatistics: Clinical trial design, biomarker validation [hu10]

Harvard Stem Cell Institute

The Harvard Stem Cell Institute (HSCI) supports neurodegeneration research through:

• iPSC Models: Induced pluripotent stem cell models of disease
• Cell Replacement Therapy: Dopaminergic neuron transplantation
• Drug Screening: High-throughput screening using stem cell derivatives [hu6]

Major Research Centers

Harvard NeuroDiscovery Center

The Harvard NeuroDiscovery Center serves as the coordinating hub for neurodegeneration research across Harvard-affiliated institutions. The center facilitates:

• Multidisciplinary research collaborations
• Shared resource access (imaging, genomics, bioinformatics)
• Training programs for clinical and basic scientists
• Industry partnerships for drug development [hu2]

Massachusetts Alzheimer's Disease Research Center (MADRC)

The MADRC, funded by the NIH National Institute on Aging, is one of the premier Alzheimer's disease research centers in the United States. The center conducts:

• Clinical research on early detection and intervention
• Neuropathology studies on post-mortem brain tissue
• Training for the next generation of AD researchers
• Community outreach and education [hu9][hu20]

Ann Romney Center for Neurologic Diseases

Located at Brigham and Women's Hospital, the Ann Romney Center focuses on:

• Alzheimer's disease therapeutic development
• Parkinson's disease biomarkers
• Multiple sclerosis mechanisms
• Novel treatment approaches [hu4]

Harvard Aging Brain Study

The Harvard Aging Brain Study is one of the world's most important longitudinal studies on preclinical Alzheimer's disease. The study has:

• Identified amyloid and tau biomarkers of preclinical AD
• Established criteria for preclinical disease staging
• Informed clinical trial design for early intervention
• Trained numerous investigators in biomarkers research [hu5][hu14]

Key Research Laboratories

Tanzi Laboratory (Massachusetts General Hospital)

Dr. Rudy Tanzi's laboratory has made seminal contributions to Alzheimer's disease genetics and therapeutics:

• Discovery of AD genes including [APP](/entities/app-protein), [PSEN1](/genes/psen1), [PSEN2](/genes/psen2)
• Identification of [gamma-secretase](/proteins/gamma-secretase) as the APP cleaving enzyme
• Research on zinc metabolism in amyloidogenesis
• Development of gamma-secretase modulators for therapy [hu11]

Hyman Laboratory (Massachusetts General Hospital)

Dr. Bradley Hyman's laboratory focuses on:

• Tau protein propagation in Alzheimer's disease
• Alzheimer's disease clinical trials
• Functional imaging biomarkers
• Synaptic dysfunction in AD [hu12]

Selkoe Laboratory (Brigham and Women's Hospital)

Dr. Dennis Selkoe's laboratory is renowned for:

• Discovery of amyloid-beta as the neurotoxic species in AD
• Soluble oligomer research
• Synaptic dysfunction mechanisms
• Therapeutic antibody development [hu15]

Sperling Laboratory (Brigham and Women's Hospital)

Dr. Reisa Sperling leads the Harvard Aging Brain Study and focuses on:

• Preclinical Alzheimer's disease biomarkers
• Amyloid and tau PET imaging
• Early intervention strategies
• Clinical trial design for prevention [hu14]

Notable Discoveries and Contributions

Historical Milestones

| Year | Discovery | Researchers |
|------|-----------|-------------|
| 1984 | Discovery of amyloid beta protein sequence | Glenner & Wong (HMS) |
| 1987 | Cloning of APP gene | Tanzi et al. |
| 1992 | Discovery of presenilin mutations causing familial AD | Tanzi et al. |
| 1995 | Discovery of PSEN2 gene | Sherrington et al. |
| 2000s | Amyloid oligomer hypothesis | Selkoe et al. |
| 2010s | Tau propagation mechanisms | Hyman et al. |
| 2020s | TREM2 microglia research | Various HMS labs |

Current Research Focus

Amyloid and Tau Biology

Harvard researchers continue to lead understanding of protein aggregation in neurodegenerative diseases:

• Amyloid-beta: Oligomer toxicity, immunotherapy targets, APP processing [hu15]
• Tau: Propagation mechanisms, strain classification, therapeutic targets [hu12]
• Alpha-synuclein: Parkinson's disease pathology, Lewy body formation [hu18]

Neuroinflammation

Research on the role of immune processes in neurodegeneration:

• TREM2: Microglial activation in AD, risk gene biology [hu17]
• Inflammasome: NLRP3 activation in neurodegeneration
• Cytokines: IL-1beta, TNF-alpha in disease progression

Genetic Risk Factors

Harvard has been instrumental in identifying genetic risk for neurodegenerative diseases:

• APOE: Risk stratification and mechanism studies
• TREM2: GWAS and functional studies [hu17]
• LRRK2: Parkinson's disease genetics [hu19]
• GBA: Gaucher's disease and PD risk

Biomarkers and Imaging

Development of biomarkers for early detection and monitoring:

• PET Imaging: Amyloid and tau PET ligands
• CSF Biomarkers: A-beta, tau, neurofilament light chain
• Blood Biomarkers: Ultra-sensitive detection methods
• Digital Biomarkers: Remote monitoring technologies

Clinical Facilities and Teaching Hospitals

Harvard's extensive clinical research infrastructure includes:

Massachusetts General Hospital (MGH)

• Memory Disorders Unit: Leading clinical program for AD
• Movement Disorders Unit: Parkinson's disease and related disorders
• Frontotemporal Disorders Unit: FTLD and PPA research
• Neuroimaging Lab: PET, MRI research facilities [hu3]

Brigham and Women's Hospital (BWH)

• Ann Romney Center for Neurologic Diseases [hu4]
• Movement Disorders Program
• Cognitive Neurology Unit
• Clinical Trials Unit [hu7]

Beth Israel Deaconess Medical Center (BIDMC)

• Alzheimer's Disease Research Center
• Parkinson's Disease and Movement Disorders Center
• Center for Brain Health

McLean Hospital

• Geriatric Psychiatry Program
• Neuroimaging Research
• Dementia with Lewy Bodies Program

Training and Education Programs

Harvard offers comprehensive training in neurodegenerative disease research:

Graduate Programs

• PhD in Neuroscience: HMS Department of Neuroscience
• PhD in Cell Biology: Molecular mechanisms of neurodegeneration
• PhD in Genetics: Genetic epidemiology of AD/PD
• PhD in Epidemiology: Neuroepidemiology [hu10]

Medical Training

• MD/PhD Program: Combined training in neurology and research
• Neurology Residency: Clinical training in neurodegenerative diseases
• Behavioral Neurology Fellowship: Cognitive disorders training
• Movement Disorders Fellowship: Parkinson's disease specialization

Postdoctoral Training

• Basic Science Postdocs: Laboratory training in neurodegeneration
• Clinical Research Postdocs: Clinical trials and biomarkers
• Data Science Postdocs: AI/ML in neuroimaging and genomics

International collaborations

Harvard researchers participate in numerous international research consortia:

Alzheimer's Disease

• International Genomics of Alzheimer's Project (IGAP): Genetic discovery
• Alzheimer's Disease Neuroimaging Initiative (ADNI): Biomarker validation
• Trial-Ready Cohorts for Preclinical/Prodromal AD: Clinical trial readiness

Parkinson's Disease

• International Parkinson's Disease Genomics Consortium (IPDGC) [hu19]
• Michael J. Fox Foundation Parkinson's Progression Markers Initiative (PPMI)
• Global Parkinson's Genetics Program (GP2)

ALS

• ALS Consortium: Genetic discovery
• Answer ALS: Comprehensive data collection

Funding and Research Support

Harvard neurodegeneration research is supported by:

• National Institutes of Health (NIH): Major funding through NIA, NINDS
• Alzheimer's Association: Research grants and fellowships
• Michael J. Fox Foundation: Parkinson's disease research
• BrightFocus Foundation: Glaucoma and AD research
• Industry Partnerships: Pharmaceutical company collaborations
• Private Foundations: Various family foundations

See Also

• [Harvard Medical School](/institutions/harvard-medical-school)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Massachusetts General Hospital](/institutions/massachusetts-general-hospital)
• [Brigham and Women's Hospital](/institutions/brigham-and-womens-hospital)
• [Rudy Tanzi](/researchers/rudy-tanzi)
• [Dennis Selkoe](/researchers/dennis-selkoe)
• [Bradley Hyman](/researchers/bradley-hyman)

References